MedTrace Logo

CEFID-II (CEra Flow Improves DVT-II)

NCT05511064 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-02-05

No results posted yet for this study

Summary

For Deep Vein Thrombosis (DVT) risk groups, the effect and safety of blood circulation improvement before and after application are evaluated using an investigational device (model name CGM MB-1701).

Conditions

  • Blood Circulation Disorder
  • Deep Vein Thrombosis

Interventions

DEVICE

Blood circulation device

Blood circulation device of CGM MB-1701

Sponsors & Collaborators

  • Ceragem Clinical Inc.

    lead INDUSTRY

Principal Investigators

  • Joon-shik Yoon, MD · Korea University Guro Hospital

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-22
Primary Completion
2024-10-28
Completion
2024-10-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05511064 on ClinicalTrials.gov